• >$6B1
    Annual Cost
  • 13M+2
    Cases / Year
  • 53.5%1,3
    Cost Escalation
  • 68%4
    Inappropriate Rx
  • 25%5
    Sepsis Cases
  • 87k5
    Associated Deaths

If this were any other condition, it would be called a public health emergency.

Yes.

It’s a crisis.

Get the Clinical Insights Report
Clinical Insights Report

The UTI Crisis:
Hidden In Plain Sight.

Findings from an expert panel on diagnostic failure, systemic burden, and the imperative for change.

We’ve normalized diagnostic failure — and it’s costing patients and the system more than we realize.

Roundtable Participants

Five voices, one diagnosis.

Spanning health policy, laboratory medicine, urology, patient advocacy, and research — convened to examine the true scope of the UTI crisis from clinical, economic, public health, and patient-centered perspectives.

  • Health Policy

    David Nash, MD, MPA

    Professor of Health Policy, Thomas Jefferson University; Founding Dean, College of Population Health; Pathnostics External Advisory Board Member

  • Laboratory Medicine

    Frank R. Cockerill, MD

    Founder, Trusted Health Advisors; Former Chair, Infectious Diseases and Laboratory Medicine Pathology; Former CEO, Mayo Clinic Laboratories

  • Urology

    Glenn Werneburg, MD, PhD

    Physician-Scientist, Urology; Incoming Director, Multidisciplinary UTI Clinic, Stony Brook University

  • Patient Advocacy & Research

    Melissa Kramer, PhD

    Founder, UTI-Free; Co-founder, Alliance for Patient-Centered UTI Research; Developer of the first validated patient-reported outcome measure for recurrent UTI

  • Patient Advocacy

    Hannah Helgeson

    Operations Manager and Board Secretary, Let’s Talk UTI; Patient Advocacy Representative

  • Moderator

    Jeremy Schubert, DSL, MPH, MBA

    Chief Commercial Officer, Pathnostics, Inc.

From the Roundtable

One Consensus.
Four Imperatives for Change.

  1. 01

    Acceptance of Misdiagnosis

    We have normalized a diagnostic failure rate that would be unacceptable in any other branch of acute medicine.

  2. 02

    Obsolete Standards

    The 70-year-old gold standard of culture is increasingly disconnected from the modern reality of complex patient profiles.

  3. 03

    Unmeasured Consequences

    The longitudinal cost of diagnostic failure — readmissions, AMR, and patient suffering — remains largely invisible to CFOs.

  4. 04

    A System Not Designed to Learn

    Real-world evidence must bridge the gap between bench science and bedside decision-making to evolve the protocol.

Read the Full Report

The complete narrative, citations,
and the case for an evolved protocol.

A short download — and a useful one to share with your clinical team, your medical director, or your board.

Get the Report →

References

  1. Carreno et al., Open Forum Infect Dis, 2019.
  2. Flores-Mireles et al., Nat Rev Microbiol, 2015; Simmering et al., Open Forum Infect Dis, 2017.
  3. Wattengel et al., Am J Infect Control, 2020.
  4. Wagenlehner et al., Int J Antimicrob Agents, 2011.
  5. Dantes et al., MMWR, 2023; StatPearls Urosepsis.
  6. Vollstedt et al., J Surg Urol, 2020.

Pathnostics, Inc. · 1298R01-0526